EOS789 + Placebo + Renvela
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Dec 1, 2016 → Aug 1, 2018
NCT ID
NCT02965053About EOS789 + Placebo + Renvela
EOS789 + Placebo + Renvela is a phase 1 stage product being developed by Chugai Pharmaceutical for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02965053. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 15 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (13)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02965053 | Phase 1 | Completed |
Competing Products
20 competing products in Hyperphosphatemia